NDUBUISI ODIMEGWU: Open Payments
NPI 1043702467 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$606 in 25 payments from 7 companies in 2025. Trend: 2023 $364 · 2024 $196 · 2025 $606
Food & beverage: $606
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $193 |
| Janssen Pharmaceuticals, Inc | 5 | $159 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| E.R. Squibb & Sons, L.L.C. | 3 | $66 |
| Alkermes, Inc. | 2 | $49 |
| AstraZeneca Pharmaceuticals LP | 3 | $45 |
| Luye Pharma (USA) Ltd. | 1 | $19 |
Products named: UZEDY, INVEGA SUSTENNA, COBENFY, ARISTADA, REXULTI, AUSTEDO XR, AIRSUPRA, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
